These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32740107)

  • 21. Attention-deficit/hyperactivity disorder and associated childhood disorders.
    Dunne JE
    Prim Care; 1999 Jun; 26(2):349-72. PubMed ID: 10318752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attention deficit hyperactivity disorder in adults.
    Rösler M; Casas M; Konofal E; Buitelaar J
    World J Biol Psychiatry; 2010 Aug; 11(5):684-98. PubMed ID: 20521876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current pharmacotherapy of attention deficit hyperactivity disorder.
    Reddy DS
    Drugs Today (Barc); 2013 Oct; 49(10):647-65. PubMed ID: 24191257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.
    Fredriksen M; Peleikis DE
    Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):23-31. PubMed ID: 26404187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.
    Chan E; Fogler JM; Hammerness PG
    JAMA; 2016 May; 315(18):1997-2008. PubMed ID: 27163988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial.
    Ni HC; Hwang Gu SL; Lin HY; Lin YJ; Yang LK; Huang HC; Gau SS
    J Psychopharmacol; 2016 May; 30(5):459-67. PubMed ID: 26905919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of attention-deficit/hyperactivity disorder in clinical practice. A retrospective study].
    López-López A; Poch-Olivé ML; López-Pisón J; Cardo-Jalón E;
    Medicina (B Aires); 2019; 79(Suppl 1):68-71. PubMed ID: 30776283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence, incidence and persistence of ADHD drug use in Japan.
    Okumura Y; Usami M; Okada T; Saito T; Negoro H; Tsujii N; Fujita J; Iida J
    Epidemiol Psychiatr Sci; 2019 Dec; 28(6):692-696. PubMed ID: 29804548
    [No Abstract]   [Full Text] [Related]  

  • 29. Updates on attention deficit hyperactivity disorder, child abuse and neglect, and sudden infant death syndrome.
    Daley KC
    Curr Opin Pediatr; 2003 Apr; 15(2):216-25. PubMed ID: 12640282
    [No Abstract]   [Full Text] [Related]  

  • 30. [Pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders].
    Wiesegger G; Kienbacher C; Pellegrini E; Scheidinger H; Vesely C; Bangerl W; Friedrich M
    Neuropsychiatr; 2007; 21(3):187-206. PubMed ID: 17915180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS; Bell EA; Erramouspe J
    Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.
    Levin FR; Mariani JJ; Specker S; Mooney M; Mahony A; Brooks DJ; Babb D; Bai Y; Eberly LE; Nunes EV; Grabowski J
    JAMA Psychiatry; 2015 Jun; 72(6):593-602. PubMed ID: 25887096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder.
    Perugi G; Vannucchi G
    Expert Opin Pharmacother; 2015; 16(14):2193-204. PubMed ID: 26364896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on adult attention-deficit/hyperactivity disorder.
    Hammerness P; Surman C; Miller K
    Curr Neurol Neurosci Rep; 2008 Nov; 8(6):484-9. PubMed ID: 18957185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
    Hennessy S; Schelleman H; Daniel GW; Bilker WB; Kimmel SE; Guevara J; Cziraky MJ; Strom BL
    Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):934-41. PubMed ID: 20623519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.
    Kollins SH
    Curr Med Res Opin; 2008 May; 24(5):1345-57. PubMed ID: 18384709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Attention deficit hyperactivity disorder in adults].
    Valdizán JR; Izaguerri-Gracia AC
    Rev Neurol; 2009 Feb; 48 Suppl 2():S95-9. PubMed ID: 19280582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis and management of adult attention-deficit/hyperactivity disorder.
    Post RE; Kurlansik SL
    Am Fam Physician; 2012 May; 85(9):890-6. PubMed ID: 22612184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding attention-deficit/hyperactivity disorder from childhood to adulthood.
    Wilens TE; Spencer TJ
    Postgrad Med; 2010 Sep; 122(5):97-109. PubMed ID: 20861593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.